PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Progestogen Therapy

HS Grampian (UK)0 个研究点目标入组 403 人开始时间: 2014年3月20日最近更新: 2024年6月3日

适应症

试验速览

2017 Other publications in https://www.ncbi.nlm.nih.gov/pubmed/28283026 Internal pilot focus group results 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38749550/ (added 21/05/2024)

•1. Women aged 16-45
•2. No immediate plans to conceive
•3. Are scheduled to have laparoscopic conservative surgery, or a diagnostic laparoscopy with concurrent surgery if endometriosis is found, for pelvic pain associated with endometriosis
•(Pilot phase) willing to be randomised to at least one long-acting progestogen (LNG-IUS/DMPA) and COCP

•Any women, who at the point of randomisation have any of the following, are not eligible for the trial:
•1. Current infertility (trying for a baby, receiving or contemplating fertility treatment)
•2. Deep infiltrating endometriosis, involving the bowel or rectovaginal septum, and requiring complex surgery, whether pre-planned or identified at laparoscopy
•3. Contraindications to the use of hormonal treatment with oestrogen or progestogens
•4. Suspicion of malignancy

发起方

HS Grampian (UK)